Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353821 · ClinicalTrials.gov registry record
Investigating Cytokine Genes of Stem Cell Donors
A clinical trial of Stem Cell Transplantation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT00353821: Completed study of Stem Cell Transplantation, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00353821 is a study of Stem Cell Transplantation that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 24 participants, below the 42-participant average among 8 other Stem Cell Transplantation trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00353821, a study of Stem Cell Transplantation, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to investigate the factors that may account for the differences in the way a stem cell recipient s immune system works after a transplant. It will focus on cytokine genes, which give specific instructions to the genes and which may influence immune system response. More specifically, the purpose of the study is to find out how gene polymorphisms (gene variations among the population) affect the success or failure of a stem cell transplant. Study participants will have donated blood for a stem cell transplant. They will be asked to give consent for NIH personnel to run special tests on these blood samples, which will have been placed in storage. It is hoped that blood samples will be studied from 600 stem cell donors.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-06-05 |
| Est. Completion | 2018-03-02 |
What the finished NCT00353821 record still lists
NCT00353821 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 42-participant average among 8 other Stem Cell Transplantation trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Stem Cell Transplantation appearing as the primary indexed condition, and to 0 interventions.
NCT00353821 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00353821 about?
NCT00353821 is a clinical study titled "Investigating Cytokine Genes of Stem Cell Donors". This study seeks to investigate the factors that may account for the differences in the way a stem cell recipient s immune system works after a transplant. It will focus on cytokine genes, which give specific instructions to the genes and which may influence immune system response. More specifically...
What is the current status of trial NCT00353821?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2003-06-05. Estimated completion is 2018-03-02.
What conditions does trial NCT00353821 study?
This clinical trial studies the following conditions: Stem Cell Transplantation.
Who is sponsoring clinical trial NCT00353821?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00353821 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00353821's enrollment target sits among peer trials
24 7th of 8 higher than 2 of 8 other Stem Cell Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stem Cell Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
ACTIVE NOT RECRUITING · NA
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility Neurocognitive Outcome After Transplant
ACTIVE NOT RECRUITING · NA
-
C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
COMPLETED
-
Post-HSCT Medication Adherence mHealth App
COMPLETED
-
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI